Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes giredestrant, a novel, next-generation selective estrogen receptor degrader and full antagonist, compared to a standard combination approach. These findings, from the phase 3 evERA Breast Cancer study, are presented today by Dr. Erica Mayer of Dana-Farber Cancer Institute at the annual meeting of the European Society for Medical Oncology (ESMO) in Berlin, Germany.

Living near toxic sites is linked to aggressive breast cancer. Can AI improve mammography interpretation? Glioblastoma cells that “unstick” from neighboring cells become more deadly, and patients who receive remote monitoring after cancer surgery have better outcomes. All of these story ideas and more are in this month’s tip sheet from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

The “tumor-on-a-chip” recreates the body’s tumor environment in miniature, complete with blood vessels and immune cells, so researchers can “see” what helps or hinders engineered immune cells inside solid tumors.

Adding vildagliptin, a drug currently used to treat type 2 diabetes, to the chip, allows many more CAR T cells to break through the protective tumor microenvironment and attack the tumor.

These chips could help accelerate the development of more efficacious and safer immunotherapies for cancer patients while reducing the need for the use of other preclinical models.

The European Society of Endocrinology (ESE) and the European Society for Paediatric Endocrinology (ESPE) have released the EndoCompass Research Roadmap: Directions for the Future of Endocrine Science. The supplement is published today in the European Journal of Endocrinology and is a major new initiative to align research efforts, improve funding strategies and increase the visibility of hormone-related health challenges across Europe.